Literature DB >> 7923188

alpha-Hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA-binding activity in rat hepatocytes.

D H Phillips1, P L Carmichael, A Hewer, K J Cole, G K Poon.   

Abstract

It has been proposed that the antiestrogen tamoxifen induces liver tumors in rats and genotoxic effects in vitro through metabolic activation involving, initially, alpha-hydroxylation of the ethyl group. To test this hypothesis, the extent of DNA adduct formation in primary rat hepatocytes treated with tamoxifen and alpha-hydroxytamoxifen was investigated. Hepatocytes from female Fischer F-344 rats were treated with 1 or 10 microM concentrations of either alpha-hydroxytamoxifen or tamoxifen. DNA was isolated and analyzed for the presence of DNA adducts by 32P postlabeling. Chromatography on polyethyleneimine cellulose thin layer chromatography and reverse-phase high performance liquid chromatography revealed that the same pattern of adducts was formed by both compounds. However, the level of adduct formation was 25 and 49 times greater with alpha-hydroxytamoxifen than with tamoxifen at 1 and 10 microM, respectively. The formation of alpha-hydroxytamoxifen as a metabolite of tamoxifen was demonstrated by mass spectrometric analysis of the extracted culture medium. alpha-Hydroxytamoxifen was found to react with DNA in the absence of metabolizing enzymes. These results demonstrate the involvement of alpha-hydroxylation in the metabolic activation of tamoxifen.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7923188

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1).

Authors:  Edwin J Squirewell; Xiaoyan Qin; Michael W Duffel
Journal:  Drug Metab Dispos       Date:  2014-08-25       Impact factor: 3.922

2.  Genotoxicity of the some selective estrogen receptor modulators: a review.

Authors:  Serkan Yilmaz; Ilknur M Gönenç; Ebru Yilmaz
Journal:  Cytotechnology       Date:  2014-03-05       Impact factor: 2.058

3.  Blockers of volume-activated Cl- currents inhibit endothelial cell proliferation.

Authors:  T Voets; G Szücs; G Droogmans; B Nilius
Journal:  Pflugers Arch       Date:  1995-11       Impact factor: 3.657

4.  Potential anti-genotoxic effect of sodium butyrate to modulate induction of DNA damage by tamoxifen citrate in rat bone marrow cells.

Authors:  Haidan M El-Shorbagy
Journal:  Cytotechnology       Date:  2016-11-30       Impact factor: 2.058

Review 5.  New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer.

Authors:  V Craig Jordan
Journal:  Steroids       Date:  2007-07-27       Impact factor: 2.668

Review 6.  Tandem mass spectrometry for characterization of covalent adducts of DNA with anticancer therapeutics.

Authors:  Catherine Silvestri; Jennifer S Brodbelt
Journal:  Mass Spectrom Rev       Date:  2012-11-13       Impact factor: 10.946

7.  Species differences in the metabolic activation of tamoxifen into genotoxic derivatives: risk assessment in women.

Authors:  F De Matteis; I N White; L L Smith
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Jul-Sep       Impact factor: 2.441

8.  Bioactivation of the cancer chemopreventive agent tamoxifen to quinone methides by cytochrome P4502B6 and identification of the modified residue on the apoprotein.

Authors:  Chitra Sridar; Jaime D'Agostino; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2012-08-31       Impact factor: 3.922

9.  Partial inhibition of estrogen-induced mammary carcinogenesis in rats by tamoxifen: balance between oxidant stress and estrogen responsiveness.

Authors:  Bhupendra Singh; Nimee K Bhat; Hari K Bhat
Journal:  PLoS One       Date:  2011-09-26       Impact factor: 3.240

10.  Idoxifene is equipotent to tamoxifen in inhibiting mammary carcinogenesis but forms lower levels of hepatic DNA adducts.

Authors:  P Pace; M Jarman; D Phillips; A Hewer; J Bliss; R C Coombes
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.